Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement
Authors' conclusion
JAKi are effective for treating IMIDs, and various compounds have recently been approved.
Study context
- Population
- Randomised placebo- or active-controlled trials of all Janus kinase inhibitors (JAKi) in immune-mediated inflammatory diseases (IMIDs), plus cohort and claims data where trials were not available182 articles
- Comparison
- JAKi vs placebo or active comparators
- Outcome
- RCTs meeting their primary endpoints
Methodological detailsupdate of the 2019 Systematic Literature Review (SLR), MEDLINE, Embase and Cochrane Library
- Update of the 2019 SLR
- MEDLINE, Embase and Cochrane Library
Main finding
As reported in the abstract
- Randomised controlled trials (RCTs) meeting their primary endpoints
- 93 of 102
- Articles included, investigating 21 JAKi in 51 IMIDs
- 182
- Phase 2 trials
- 43
- Phase 3 trials
- 59
- Strategic trials
- 9
- Pilot or cohort studies and case series
- 72
Further findings
Regulatory approvals since 2019
- JAKi approved by FDA and EMA
- 8
- IMIDs with new JAKi approval
- 11
- IMIDs without previously approved disease-modifying antirheumatic drug (DMARD) therapy
- 2
Original publication
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement. Ann Rheum Dis. Published 10 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →